Purdue University — Imatinib Trial for Drug-Resistant Malaria (2023)

Purdue University
Award Date:
To support a phase IIa/IIb trial of the drug imatinib.

Open Philanthropy recommended a gift of $780,000 over three years to Purdue University to support a phase IIa/IIb trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Africa. This research will be coordinated by Professor Philip Low, who previously organized a successful phase II trial of imatinib (and an ongoing phase III trial) in Vietnam.

This follows Open Philanthropy’s September 2022 support and falls within its focus area of scientific research, specifically within its interest in advancing human health and wellbeing.

Read more: